A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis

NCT05359393 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Advanced Rectal Cancer
Liver Metastasis
Pulmonary Metastasis
Microsatellite Stable Colorectal Carcinoma

Interventions

COMBINATION_PRODUCT: a combination therapy including tislelizumab

Sponsor

Fudan University